检索结果-南通市图书馆

World Journal of Clinical Cases 2021年第4期9卷 919-926页

作者： Yu Zhang Di Wu Bo Zhao Xue-Liang Tian Tian-Cheng Yao Feng Li Wei-Fang Liu Ai-Ping Shi Department of Breast Surgery The First Hospital of Jilin UniversityChangchun 130021Jilin ProvinceChina

BACKGROUND Occult breast cancer(OBC)is a special type of breast cancer presenting as axillary lymph node metastasis with undetectable primary lesions in the *** to its low incidence and unique clinical manifestations,there is a lack of consensus on the diagnosis and treatment of *** report a case of OBC treated with neoadjuvant chemotherapy combined with *** treatment was well tolerated,and the patient achieved a pathologic complete *** SUMMARY A 53-year-old woman presented with a lump in her right axillary area with no primary lesions in the *** biopsy confirmed right axillary metastatic *** staining results were positive for progesterone receptor,cytokeratin 7,specific breast markers GATA3 and gross cystic disease fluid *** cells were negative for estrogen receptor,human epidermal growth factor receptor-2,cytokeratin 5/6,cytokeratin 20,and *** patient was diagnosed with OBC,and she underwent neoadjuvant chemotherapy combined with *** plus axillary lymph node dissection was *** patient achieved pathologic complete response with no residual invasive tumor cells in the breast or axillary lymph ***,she received adjuvant radiotherapy and endocrine *** neoadjuvant chemotherapy and anlotinib had good efficacy and safety in the treatment of OBC and may be a new therapeutic option.

关键词： Occult breast cancer neoadjuvant chemotherapy Anlotinib Mastectomy Pathological complete response Case report

Alterations in Serum Lipids and Lipoproteins Induced by neoadjuvant chemotherapy in Patients with Osteosarcoma around the Knee Joint:A Retrospective Analysis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Current Medical Science 2024年第4期44卷 741-747页

作者： Su-guo WANG Yong-gang WANG Guo-wei QIAN Li-na TANG Xin ZHOU Dong-dong CHENG Chen-liang ZHOU Qing-cheng YANG Zan SHEN Gao-zhong HUANG Hong-tao LI Department of General Medicine Shenzhen Third People's HospitalShenzhen 518112China Department of VIP Clinic Shanghai Jiao Tong University Afiliated Sixth People's HospitalShanghai 200233China Department of Oncology Shanghai Jiao Tong University Affiliated Sixth People's HospitalShanghai 200233China Cancer Research Institute of Jilin University the First Hospital of Jilin UniversityChangchun 130021China Department of Orthopedics Shanghai Jiao Tong University Afiliated Sixth People's HospitalShanghai 200233China

Objective To investigate the serum lipid profiles of patients with localized osteosarcoma around the knee joint before and after neoadjuvant *** After retrospectively screening the data of 742 patients between January 2007 and July 2020,50 patients aged 13 to 39 years with Enneking stage II disease were included in the *** lipid levels,including total cholesterol(TC),triglycerides(TG),high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C),lipoprotein-α[Lp(a)],and apolipoprotein A1,B,and E(ApoA1,ApoB,and ApoE),and clinicopathological characteristics were collected before and after neoadjuvant *** The mean levels of TC,TG,and ApoB were significantly increased following neoadjuvant chemotherapy(16%,38%,and 20%,respectively,*** values;Pchemotherapy,although this difference was not statistically significant(P=0.23 and P=0.24,respectively).Conclusion Significant elevations in serum lipids were observed after neoadjuvant chemotherapy in patients with localized *** was no prognostic significance of pretreatment serum lipid levels on histologic response to neoadjuvant *** scale of increase in serum Lp(a)might have a potential prognostic role in *** with increased LDL-C or reduced TG after chemotherapy seem to exhibit a trend toward favorable DFS.

关键词： osteosarcoma neoadjuvant chemotherapy serum lipids

Development of a novel staging classification for Siewert Ⅱ adenocarcinoma of the esophagogastric junction after neoadjuvant chemotherapy

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Oncology 2024年第6期16卷 2541-2554页

作者： Jian Zhang Hao Liu Hang Yu Wei-Xiang Xu Department of Gastrointestinal Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003Zhejiang ProvinceChina

BACKGROUND Stage classification for Siewert Ⅱ adenocarcinoma of the esophagogastric junction(AEG)treated with neoadjuvant chemotherapy(NAC)has not been *** To investigate the optimal stage classification for Siewert Ⅱ AEG with *** A nomogram was established based on Cox regression model that analyzed variables associated with overall survival(OS)and disease-specific survival(DSS).The nomogram performance in terms of discrimination and calibration ability was evaluated using the likelihood-ratio test,Akaike information criterion,Harrell concordance index,time-receiver operating characteristic curve,and decision curve *** Data from 725 patients with Siewert type Ⅱ AEG who underwent neoadjuvant therapy and gastrectomy were obtained from the Surveillance,Epidemiology,and End Results *** and multivariate analyses revealed that sex,marital status,race,ypT stage,and ypN stage were independent prognostic factors of OS,whereas sex,race,ypT stage,and ypN stage were independent prognostic factors for *** factors were incorporated into the OS and DSS *** novel nomogram model performed better in terms of OS and DSS prediction compared to the 8th American Joint Committee of Cancer pathological staging system for esophageal and gastric ***,a user-friendly web application was developed for clinical *** The nomogram established specifically for patients with Siewert type Ⅱ AEG receiving NAC demonstrated good prognostic *** using external data is warranted before its widespread clinical application.

关键词： Stage classification Prognosis Esophagogastric junction cancer neoadjuvant chemotherapy Siewert type

Genetic mutations associated with sensitivity to neoadjuvant chemotherapy in metastatic colon cancer:A case report and review of literature

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2021年第24期9卷 7099-7109页

作者： Long Zhao Quan Wang Shi-Dong Zhao Jing Zhou Ke-Wei Jiang Ying-Jiang Ye Shan Wang Zhan-Long Shen Department of Gastroenterological Surgery Laboratory of Surgical OncologyBeijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment ResearchPeking University People's HospitalBeijing 100044China

BACKGROUND Colorectal liver metastases(CLM)occur in 15%-30%of patients with colorectal cancer(CRC).Advancements in next generation sequencing(NGS)can provide more precise prognoses for cancer patients and help guide clinical ***,the genetic variants that predict high sensitivity to neoadjuvant chemotherapy remain unclear,especially in patients with *** aim of this study was to identify the relevant genetic variants in a single CLM patient and to summarize the current evidence on mutations and single nucleotide polymorphisms(SNPs)that objectively predict sensitivity to neoadjuvant *** SUMMARY A 76-year-old male patient,who was diagnosed as stage IV colon cancer with liver metastases,was found to have APC/TP53/KRAS *** showed a good therapeutic response to 12 courses of oxaliplatin regimens combined with *** analysis of the patient identified 5 genes with 7 detected SNPs that may be related to a better response to chemotherapy *** addition,a critical literature review was performed based on a standardized appraisal form after selecting the ***,21 eligible studies were appraised to assess the association between gene mutations and good *** in KRAS,TP53,SMAD4,and APC were identified as being associated with a poor response to chemotherapy drugs,whereas mutations of CREBBP and POLD1 were associated with longer overall *** NGS can identify precise predictors of response to neoadjuvant chemotherapy,leading to improved outcomes for CRC patients.

关键词： Colorectal liver metastases Next generation sequencing neoadjuvant chemotherapy Genetic variants Case report

Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2020年第19期26卷 2388-2402页

作者： Zheng-Yan Li Xiao-Dong Wang Mou Li Xi-Jiao Liu Zheng Ye Bin Song Fang Yuan Yuan Yuan Chun-Chao Xia Xin Zhang Qian Li Department of Radiology West China Hospital of Sichuan UniversityChengdu 610041Sichuan ProvinceChina Department of Gastrointestinal Surgery West China Hospital of Sichuan UniversityChengdu 610041Sichuan ProvinceChina Life Science PDxIPM teamGE HealthcareShanghai 210000China

BACKGROUND neoadjuvant chemotherapy is currently recommended as preoperative treatment for locally advanced rectal cancer(LARC);however,evaluation of treatment response to neoadjuvant chemotherapy is still *** To create a multi-modal radiomics model to assess therapeutic response after neoadjuvant chemotherapy for *** This retrospective study consecutively included 118 patients with LARC who underwent both computed tomography(CT)and magnetic resonance imaging(MRI)before neoadjuvant chemotherapy between October 2016 and June *** findings were used as the reference standard for pathological *** were randomly divided into a training set(n=70)and a validation set(n=48).The performance of different models based on CT and MRI,including apparent diffusion coefficient(ADC),dynamic contrast enhanced T1 images(DCE-T1),high resolution T2-weighted imaging(HR-T2WI),and imaging features,was assessed by using the receiver operating characteristic curve *** was demonstrated as area under the curve(AUC)and accuracy(ACC).Calibration plots with Hosmer-Lemeshow tests were used to investigate the agreement and performance characteristics of the *** Eighty out of 118 patients(68%)achieved a pathological *** an individual radiomics model,HR-T2WI performed better(AUC=0.859,ACC=0.896)than CT(AUC=0.766,ACC=0.792),DCE-T1(AUC=0.812,ACC=0.854),and ADC(AUC=0.828,ACC=0.833)in the validation *** imaging performance for extramural venous invasion detection was relatively low in both the training(AUC=0.73,ACC=0.714)and validation(AUC=0.578,ACC=0.583)*** multi-modal radiomics model reached an AUC of 0.925 and ACC of 0.886 in the training set,and an AUC of 0.93 and ACC of 0.875 in the validation *** the clinical radiomics nomogram,good agreement was found between the nomogram prediction and actual *** A multi-modal nomogram using traditional imaging features and radiomics of preoperati

关键词： Radiomics Rectal cancer neoadjuvant chemotherapy Magnetic resonance imaging Computed tomography

Ki-67 Change in Anthracyline-containing neoadjuvant chemotherapy Response in Breast Cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Current Medical Science 2024年第1期44卷 156-167页

作者： Zi-guo YANG Le-hao REN Feng WANG Pi-lin WANG Wen-yan WANG Shu-ye LIN Department of General Surgery Beijing Tiantan HospitalCapital Medical UniversityBeijing 100070China Department of Critical Care Medicine Union HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022China Cancer Research Center Beijing Chest HospitalCapital Medical University/Beijing Tuberculosis and Thoracic Tumor Research InstituteBeijing 101149China

Objective Anthracycline-containing regimens are irreplaceable in neoadjuvant chemotherapy(NAC)for breast cancer(BC)at ***,30% of early breast cancer(EBC)patients are resistant to anthracycline-containing chemotherapy,leading to poor prognosis and higher ***-67 is associated with the prognosis and response to therapy,and it changes after *** A total of 105 BC patients who received anthracycline-containing NAC were ***,the optimal model of Ki-67 was selected,and its predictive efficacy was ***(IHC)was used to determine the estrogen receptor(ER),progesterone receptor(PR),and human epidermal growth factor receptor 2(HER-2)status and Ki-67 *** in situ hybridization(FISH)was used to verify the HER-2 when the IHC score was 2+.Results The post-NAC Ki67 level after treatment with anthracycline drugs was lower than pre-NAC Ki-67(19.6%±23.3%vs.45.6%±23.1%,P<0.001).Furthermore,patients with the Ki-67 decrease had a border line higher pathological complete response(pCR)rate(17.2%vs.0.0%,P=0.068),and a higher overall response rate(ORR)(73.6%vs.27.8%,P<0.001),when compared to patients without the Ki-67 *** ΔKi-67 and ΔKi-67%were valuable markers for the prediction of both the pCR rate and *** area under the curve(AUC)for ΔKi-67 on pCR and ORR was 0.809(0.698-0.921)and 0.755(0.655-0.855),respectively,while the AUC for ΔKi-67% on pCR and ORR was 0.857(0.742-0.972)and 0.720(0.618-0.822),*** logistic regression model 1 revealed thatΔKi-67 was an independent predictor for both pCR[odds ratio(OR)=61.030,95% confidence interval(CI)=4.709-790.965;P=0.002]and ORR(OR=10.001,95%CI:3.044-32.858;P<0.001).Multivariate logistic regression model 2 revealed thatΔKi-67%was also an independent predictor for both pCR(OR=408.922,95%CI=8.908-18771.224;P=0.002)and ORR(OR=5.419,95%CI=1.842-15.943;P=0.002).Conclusions The present study results suggest thatΔKi67 andΔKi67%are candidate predictor

关键词： breast cancer change in Ki-67 neoadjuvant chemotherapy anthracycline,response

Change in neoadjuvant chemotherapy could alter the prognosis of patients with pancreatic adenocarcinoma: A case report

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2021年第14期9卷 3418-3423页

作者： Alberto Meyer Bárbara J Carvalho Kayo AA Medeiros Leonardo Z Pipek Fernanda S Nascimento Milena O Suzuki João VT Munhoz Leandro R Iuamoto Luiz A Carneiro-D'Alburquerque Wellington Andraus Gastroenterologia Hospital das Clínicas HCFMUSPFaculdade de MedicinaUniversidade de São PauloSão Paulo 01426-010Brazil Gastroenterologia Faculdade de Medicinada Universidade de São PauloSão Paulo 05403-000Brazil Orthopaedics and Traumatology Faculdade de Medicinada Universidade de São PauloSão Paulo 05403-000Brazil

BACKGROUND neoadjuvant treatment has become a standard of care for borderline or locally advanced pancreatic cancer and is increasingly considered even for up-front resectable *** aim of this article is to present the case of a 62-year-old patient with locally advanced pancreatic adenocarcinoma who was successfully treated with gemcitabine plus nab-paclitaxel after the failure of the first line *** SUMMARY Computerized tomography scan and magnetic resonance imaging demonstrated a nodular lesion of ill-defined limits in the body of the pancreas,measuring approximately 4.2 cm×2.7 cm,with an infiltrative *** tumor had contact with the superior mesenteric vein,splenomesenteric junction and the proximal segment of the splenic artery,causing focal reduction of its *** to vascular involvement,neoadjuvant chemotherapy treatment with eight cycles of“folinic acid,5-fluorouracil,irinotecan and oxa-liplatine”(FOLFIRINOX)were *** the end of the cycles,surgery was performed,but the procedure was interrupted due to finding of lesions suspected of *** plus nab-paclitaxel was then successfully used for neoadjuvant treatment with subsequent R0 surgical *** Gemcitabine plus nab-paclitaxel may be effective as an alternative regimen when FOLFIRINOX fails as the first line of treatment,suggesting the need for further studies to identify which patients would benefit from each type of therapeutic approach.

关键词： neoadjuvant chemotherapy Pancreatic cancer Resectable pancreatic cancer Borderline resectable neoadjuvant Pancreas Case report

Preoperative neoadjuvant chemotherapy in patients with breast cancer evaluated using strain ultrasonic elastography

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2022年第21期10卷 7293-7301页

作者： Hong-Yu Pan Qian Zhang Wen-Jing Wu Xia Li Department of Ultrasound Wuhan Fourth HospitalPuai HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430000Hubei ProvinceChina

BACKGROUND The incidence of breast cancer in China is increasing while its mortality rate is *** annual breast cancer incidence in China is 39.2 million,accounting for two-thirds of the urban *** China,breast cancer is the fifth most common malignant tumor overall and the most common in women,accounting for 17%of female malignant *** To investigate the accuracy of strain ultrasound elastography(SUE)on the evaluation of preoperative neoadjuvant chemotherapy(NAC)in breast *** Overall,90 patients with breast cancer treated at our hospital between January 2018 and February 2019 were selected for this *** patients received six cycles of NAC with docetaxel,epirubicin,and *** treatment was also performed,and pathological reactivity was *** patients were evaluated using conventional ultrasonography and SUE before *** differences between groups were analyzed to calculate the mean and standard deviation with significance measured using a t-test,while multivariate analysis was performed using logistic regression *** Of the patients analyzed,20 had a pathological complete remission(pCR)while 70 did not achieve pCR after *** ratio of the elastic strain ratio(SR)and elastic score of 4–5 in patients with pCR were 5.5±1.16 and 15.00%,respectively;these were significantly lower than those in patients without pCR(85%)and significantly higher than in patients without pCR(14%).SR and elastic score 4–5 were independent factors influencing NAC efficacy(OR=0.644,1.426 and 1.366,respectively,P<0.05).SR was positively correlated with elasticity score(rs=0.411,P<0.05).The area under the receiver operator characteristic curve of SR and SR combined with elastic score in predicting patients without pCR was 0.822 and 0.891,respectively(P<0.05).CONCLUSION Strain ultrasonic elastography may be used to evaluate the effects of preoperative NAC in patients with breast cancer.

关键词： Breast cancer Curative effect neoadjuvant chemotherapy Strain ultrasonic elastography

Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2020年第19期26卷 2427-2439页

作者： Yong-He Chen Jian Xiao Xi-Jie Chen Hua-She Wang Dan Liu Jun Xiang Jun-Sheng Peng Department of Gastrointestinal Surgery The Sixth Affiliated HospitalSun Yat-sen UniversityGuangzhou 510655Guangdong ProvinceChina Guangdong Institute of Gastroenterology Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor DiseasesGuangzhou 510655Guangdong ProvinceChina Department of Medical Oncology The Sixth Affiliated HospitalSun Yat-sen UniversityGuangzhou 510655Guangdong ProvinceChina Department of Laboratory Science The Second Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou 510655Guangdong ProvinceChina

BACKGROUND Survival benefit of neoadjuvant chemotherapy(NAC)for advanced gastric cancer(AGC)is a debatable *** have shown that the survival benefit of NAC is dependent on the pathological response to chemotherapy *** those who achieve pathological complete response(pCR),NAC significantly prolonged prolapsed-free survival and overall *** those with poor response,NAC yielded no survival benefit,only toxicity and increased risk for tumor progression during chemotherapy,which may hinder surgical ***,predicting pCR to NAC is of great clinical significance and can help achieve individualized treatment in AGC *** To establish a nomogram for predicting pCR to NAC for AGC *** Two-hundred and eight patients diagnosed with AGC who received NAC followed by resection surgery from March 2012 to July 2019 were enrolled in this *** clinical data were retrospectively analyzed by logistic regression analysis to determine the possible predictors for *** on these predictors,a nomogram model was developed and internally validated using the bootstrap *** pCR was confirmed in 27 patients(27/208,13.0%).Multivariate logistic regression analysis showed that higher carcinoembryonic antigen level,lymphocyte ratio,lower monocyte count and tumor differentiation grade were associated with higher *** statistic of the established nomogram was *** A nomogram predicting pCR to NAC was *** this nomogram exhibited satisfactory predictive power despite utilizing easily available pretreatment parameters,it can be inferred that this nomogram is practical for the development of personalized treatment strategy for AGC patients.

关键词： Advanced gastric cancer neoadjuvant chemotherapy Nomogram Pathological complete response

Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer:an interim analysis of a phase Ⅲ randomized clinical trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Communications 2024年第10期44卷 1214-1227页

作者： Yan Zheng Guanghui Liang Dongfeng Yuan Xianben Liu Yufeng Ba Zimin Qin Sining Shen Zhenxuan Li Haibo Sun Baoxing Liu Quanli Gao Peng Li Zongfei Wang Shilei Liu Jianping Zhu Haoran Wang Haibo Ma Zhenzhen Liu Fei Zhao Jun Zhang He Zhang Daoyuan Wu Jinrong Qu Jie Ma Peng Zhang Wenjie Ma Ming Yan Yongkui Yu Qing Li Jiangong Zhang Wenqun Xing Department of Thoracic Surgery The Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouHenanP.R.China Department of Immunotherapy The Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouHenanP.R.China Department of Endoscopy The Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouHenanP.R.China Department of Pathology The Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouHenanP.R.China Department of Radiology The Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouHenanP.R.China Department of Biobank The Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouHenanP.R.China Department of Strategic Development The Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouHenanP.R.China Department of Statistics LinkDoc Technology Co.LtdBeijingP.R.China Department of Cancer Epidemiology The Affiliated Cancer Hospital of Zhengzhou UniversityHenan Cancer HospitalZhengzhouP.R.China

Background:In the era of immunotherapy,neoadjuvant immunochemotherapy(NAIC)for the treatment of locally advanced esophageal squamous cell carcinoma(ESCC)is used clinically but lacks of high-level clinical *** study aimed to compare the safety and long-term efficacy of NAIC followed byminimally invasive esophagectomy(MIE)with those of neoadjuvant chemotherapy(NAC)followed by ***:A prospective,single-center,open-label,randomized phase Ⅲ clinical trial was conducted at Henan Cancer Hospital,Zhengzhou,*** were randomly assigned to receive either neoadjuvant toripalimab(240mg)plus paclitaxel(175 mg/m^(2))+cisplatin(75 mg/m^(2))(toripalimab group)or paclitaxel+cisplatin alone(chemotherapy group)every 3 weeks for 2 *** surgery,the toripalimab group received toripalimab(240 mg every 3 weeks for up to 6 months).The primary endpoint was event-free survival(EFS).The pathological complete response(pCR)and overall survival(OS)were key secondary *** events(AEs)and quality of life were also ***:Between May 15,2020 and August 13,2021,252 ESCC patients ranging fromT1N1-3M0 to T2-3N0-3M0were enrolled for interim analysis,with 127 in the toripalimab group and 125 in the chemotherapy *** 1-year EFS rate was 77.9%in the toripalimab group compared to 64.3%in the chemotherapy group(hazard ratio[HR]=0.62;95%confidence interval[CI]=0.39 to 1.00;P=0.05).The 1-year OS rates were 94.1%and 83.0%in the toripalimab and chemotherapy groups,respectively(HR=0.48;95%CI=0.24 to 0.97;P=0.037).The patients in the toripalimab group had a higher pCR rate(18.6%vs.4.6%;P=0.001).The rates of postoperative Clavien-Dindo grade Ⅲb or higher morbidity were 9.8%in the toripalimab group and 6.8%in the chemotherapy group,with no significant difference observed(P=0.460).The rates of grade 3 or 4 treatment-related AEs did not differ between the two groups(12.5%versus 12.4%).Conclusions:The interim results of this ongoing trial showed that in resec

关键词： esophageal squamous cell carcinoma minimally invasive esophagectomy neoadjuvant chemotherapy neoadjuvant immunochemotherapy survival